share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC ·  Aug 21 07:10

Summary by Moomoo AI

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the launch of its gastrointestinal drug Talicia in the United Arab Emirates (UAE) for the treatment of Helicobacter pylori (H. pylori) infection in adults. The commercial release of Talicia in the UAE, as reported on August 21, 2024, enables RedHill to receive additional potential milestone payments, minimum sales payments, and tiered royalties on net sales. Talicia is the first low-dose rifabutin-containing combination treatment approved in the UAE and is already the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori, which affects over 50% of the global adult population. The launch in the UAE is part of RedHill's ongoing efforts to make Talicia available globally, addressing the...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the launch of its gastrointestinal drug Talicia in the United Arab Emirates (UAE) for the treatment of Helicobacter pylori (H. pylori) infection in adults. The commercial release of Talicia in the UAE, as reported on August 21, 2024, enables RedHill to receive additional potential milestone payments, minimum sales payments, and tiered royalties on net sales. Talicia is the first low-dose rifabutin-containing combination treatment approved in the UAE and is already the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori, which affects over 50% of the global adult population. The launch in the UAE is part of RedHill's ongoing efforts to make Talicia available globally, addressing the significant medical need for an effective first-line therapy due to the high resistance of H. pylori to commonly used antibiotics like clarithromycin. Talicia's approval by the U.S. FDA in November 2019 and its eligibility for eight years of U.S. market exclusivity under its QIDP designation, along with patent protection extending until 2034, positions the drug favorably in the market. RedHill continues to focus on gastrointestinal and infectious diseases, with key late-stage development programs for various conditions.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated